Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06545097 · ClinicalTrials.gov registry record · Phase 3
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
A Phase 3 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 279
- Enrollment target
NCT06545097: Completed Phase 3 study, sponsored by Tris Pharma.
NCT06545097 is a Phase 3 study that has completed, run by Tris Pharma. The registered enrollment target is 279 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06545097, a Phase 3 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 279 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.
Primary Outcome
Pain Numerical Rate Scale (NRS) area under the curve from 4 through 48 hours (AUC4-48)
Interventions
- DRUG Placebo
- DRUG Cebranopadol 400 ug
- DRUG Cebranopadol 200 ug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 3 |
What the finished NCT06545097 record still lists
NCT06545097 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06545097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06545097 about?
NCT06545097 is a clinical study titled "A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty". The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.
What is the current status of trial NCT06545097?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 279 participants. The study started on 2024-09-03. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT06545097?
The interventions under investigation include: Placebo (DRUG), Cebranopadol 400 ug (DRUG), Cebranopadol 200 ug (DRUG).
Who is sponsoring clinical trial NCT06545097?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06545097's enrollment target sits among peer trials
279 1199th of 2000 higher than 801 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI